Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 4(3)

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00176943Phase 4Completed

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

Role: lead

NCT00176956Phase 3Terminated

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

Role: lead

NCT00177060Phase 1Terminated

Topical Hydromorphone for Wound Healing

Role: lead

NCT00176982Phase 4Completed

Plaquenil for Alopecia Areata, Alopecia Totalis

Role: lead

NCT00176995Phase 2Completed

Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae

Role: lead

NCT00177099Phase 1Completed

Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice

Role: lead

NCT00177021Phase 4Completed

Aldara for the Treatment of Extensive Alopecia Areata

Role: lead

All 7 trials loaded